Description |
ANA971, an orally administered prodrug of isatoribine. Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection. ANA971 is a prodrug designed to improve the oral bioavailability of isatoribine. ANA971 resulted in higher levels of isatoribine in the blood than were present after oral administration of isatoribine itself.
|
